^
Association details:
| Biomarker: | EZH2 Y641 |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | DW91170 (EZH2 inhibitor, EZH1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
6275 / 13 - DW91170: A novel potent EZH1/2 dual inhibitor for lymphoma treatment
Published date:
03/15/2023
Excerpt:
In Pfeiffer (A677 mutation) and WSU-DLCL2 (Y641 mutation) CDX models, DW91170 showed improved tumor regression activity with no significant abnormal signs such as weight loss.
